Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1571368 | 1.00 | KDM4E (0.32) | KDM4EMAPK1HIF1APAOXMTNR1A | |
| SCHEMBL1571366 | 1.00 | KDM4E (0.32) | KDM4EMAPK1HIF1APAOXMTNR1A | |
| SCHEMBL13540157 | 0.74 | — | — | |
| SCHEMBL12946987 | 0.72 | — | — | |
| SCHEMBL1571503 | 0.71 | — | — | |
| SCHEMBL1571508 | 0.71 | — | — | |
| SCHEMBL10334348 | 0.68 | — | — | |
| SCHEMBL18760857 | 0.66 | — | — | |
| SCHEMBL7006520 | 0.64 | — | — | |
| SCHEMBL78087 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307355-B1 | Novel synthesis of substituted 4-amino-pyrimidines | DSM IP ASSETS BV (NL) | 2013-11-06 | — | — | EP | disclosed |
| US-8252927-B2 | Synthesis of substituted 4-amino-pyrimidines | DSM IP ASSETS B.V. (NL) | 2012-08-28 | — | — | US | disclosed |
| US-8252927-B2 | Synthesis of substituted 4-amino-pyrimidines | DSM IP ASSETS B.V. (NL) | 2012-08-28 | — | — | US | disclosed |
| US-20110178300-A1 | NOVEL SYNTHESIS OF SUBSTITUTED 4-AMINO-PYRIMIDINES | DSM IP ASSETS B.V. (NL) | 2011-07-21 | — | — | US | disclosed |
| US-20110178300-A1 | NOVEL SYNTHESIS OF SUBSTITUTED 4-AMINO-PYRIMIDINES | DSM IP ASSETS B.V. (NL) | 2011-07-21 | — | — | US | disclosed |
| EP-2307355-A1 | Novel synthesis of substituted 4-amino-pyrimidines | DSM IP Assets B.V. (NL) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010010113-A1 | Novel synthesis of substituted 4-amino-pyrimidines | DSM IP ASSETS B.V. (NL) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178300-A1 | NOVEL SYNTHESIS OF SUBSTITUTED 4-AMINO-PYRIMIDINES | IL4I1, CCNB1, VKORC1 | KDM4E 951/4885MAPK1 1098/4885HIF1A 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.